Ocular Therapeutix, Inc (OCUL): Total Assets
$808.06M
As of 2025-12-31
$671.32M
As of 2026-06-30
+75.6%
3-year compound annual growth
+25.3%
5-year compound annual growth
+22.0%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $808.06M | +76.5% | 2026-02-05, Balance as of period end |
| 2024-12-31 | $457.94M | +81.7% | 2026-02-05, Balance as of period end |
| 2023-12-31 | $252.06M | +68.8% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $149.29M | -27.1% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $204.89M | -21.8% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $261.86M | +232.6% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $78.74M | +7.8% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $73.04M | +31.8% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $55.43M | -26.0% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $74.94M | -32.1% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $110.31M | +41.1% | 2017-03-10, Balance as of period end |
| 2014-12-31 | $78.19M | +308.4% | 2016-03-10, Balance as of period end |
| 2013-12-31 | $19.15M | n/a | 2015-03-20, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $808.06M | +76.5% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $61.78M | -33.1% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $1.30B | -22.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $184.99M | -38.0% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $280.41M | -7.7% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $172.25M | -45.4% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $105.01M | -15.4% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $668.19M | -10.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $596.19M | +30.6% |
Compare OCUL, QTTB, AGIO, LXRX side by side · Screen every company in Pharmaceutical Preparations ↗